369593-26-0

Basic information

• Product Name: Benzofuran-2-carboxylic acid {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide
• Synonyms: Benzofuran-2-carboxylic acid {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide
• CAS NO: 369593-26-0
• Molecular Weight: 562.646
• Mol File: 369593-26-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Benzofuran-2-carboxylic acid {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide(CAS DataBase Reference)
• NIST Chemistry Reference: Benzofuran-2-carboxylic acid {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide(369593-26-0)
• EPA Substance Registry System: Benzofuran-2-carboxylic acid {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide(369593-26-0)

Safety Data

• Hazardous Substances Data: 369593-26-0(Hazardous Substances Data)

Upstream product

• 150989-61-0 4(R,S)-amino-3(R,S)-hydroxyazepane-1-carboxylic acid benzyl ester 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 369593-24-8 {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-phenylethyl}carbamic acid tert-butyl ester 
• 281221-20-3 4-tert-butoxycarbonylamino-3-hydroxy-azepane-1-carboxylic acid benzyl ester 
• 281221-22-5 [3-Hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-carbamic acid tert-butyl ester 
• 281221-21-4 (3-Hydroxy-azepan-4-yl)-carbamic acid tert-butyl ester 
• 496-41-3 Benzofuran-2-carboxylic acid 

Relevant articles and documents

Azepanone-based inhibitors of human cathepsin L

The extension of a previously reported cathepsin K azepanone-based inhibitor template to the design and synthesis of potent and selective inhibitors of the homologous cysteine protease cathepsin L is detailed. Structure-activity studies examining the effect of inhibitor selectivity as a function of the P3 and P2 binding elements of the potent cathepsin K inhibitor 1 revealed that incorporation of either a P3 quinoline-8-carboxamide or a naphthylene-1-carboxamide led to increased selectivity for cathepsin L over cathepsin K. Substitution of the P2 leucine of 1 with either a phenylalanine or a β-naphthylalanine also resulted in an increased selectivity for cathepsin L over cathepsin K. Molecular modeling studies with the inhibitors docked within the active sites of both cathepsins L and K have rationalized the observed selectivities. Optimization of cathepsin L binding by the combination of the P3 naphthylene-1-carboxamide with the P2 β-naphthylalanine provided 15, which is a potent, selective, and competitive inhibitor of human cathepsin L with a Ki = 0.43 nM.